Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir with peginterferon alfa-2b and ribavirin in treatment-naive pediatric hepatitis C genotype 1
2010-024260-17Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of boceprevir, peginterferon alfa-2b and ribavirin in chronic hepatitis C virus infection, sponsored by Merck & Co. Primary endpoint: Sustained viral response at follow-up week 24. Started Aug 2012; status: terminated.
02
Drugs
boceprevirpeginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2010-024260-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024260-17.